Awaiting development: Guidance and quality standards
Showing 331 to 340 of 389
| Title | Type |
|---|---|
| Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748] | Technology appraisal guidance |
| Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191] | Technology appraisal guidance |
| Technologies to improve detection of endometrial cancer | HealthTech guidance |
| Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201] | Technology appraisal guidance |
| Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403] | Technology appraisal guidance |
| Thyroid disease | Quality standard |
| Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915] | Technology appraisal guidance |
| Tildrakizumab for treating active psoriatic arthritis [ID6724] | Technology appraisal guidance |
| Timrepigene emparvovec for treating choroideremia [ID3916] | Technology appraisal guidance |
| Tinnitus | Quality standard |